1. Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status
- Author
-
Eun Jong Cha, Seok Joong Yun, Tae Gyun Kwon, Dong Hee Ryu, Pildu Jeong, Wun-Jae Kim, Yun-Sok Ha, Ho Won Kang, Yung Hyun Choi, Tae-Hwan Kim, Cheol Park, Ye-Hwan Kim, Sung Kwon Moon, and Won-Tae Kim
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Oncology ,congenital, hereditary, and neonatal diseases and abnormalities ,Cancer Research ,medicine.medical_specialty ,Biology ,medicine.disease_cause ,03 medical and health sciences ,Exon ,0302 clinical medicine ,Internal medicine ,Gene expression ,medicine ,Mutation ,Bladder cancer ,Oncogene ,Cancer ,Articles ,Fibroblast growth factor receptor 3 ,musculoskeletal system ,medicine.disease ,stomatognathic diseases ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,Carcinogenesis - Abstract
The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing and FGFR3 mRNA expression level was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The results were compared with the clinicopathological parameters, and the prognostic value of FGFR3 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression test. FGFR3 mutations were identified in 48/120 (40.0%) patients with pT1 BC. FGFR3 mRNA expression level was significantly higher in those with BC harboring FGFR3 mutations (P
- Published
- 2017
- Full Text
- View/download PDF